Praxis Precision Medicines Inc.
Praxis Precision Medicines Reports Topline RADIANT Study Results and Second Quarter 2025 Financial Results
Summary
Praxis Precision Medicines, Inc. announced the topline results from its RADIANT study on August 4, 2025, which showed a 56.3% median reduction in seizure frequency in patients with focal onset seizures after eight weeks of treatment with vormatrigine. Approximately 22% of patients achieved a 100% reduction in seizure frequency in the last 28 days, with the treatment being well-tolerated and showing a favorable safety profile. The company also reported its second quarter 2025 financial results, which included a net loss of $71.1 million and $446.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement